Articles & Video
Look for new trial designs and changing CRA skills in 2022 says Syneos
Patient-powered study designs and changing roles for CRAs will shape the clinical trials sector in 2022 according to Syneos Health.
Livingbridge backs UK biostats CRO Veramed
Private equity group Livingbridge has invested in UK biostatistics and programming CRO Veramed.
Thread buys Modus Outcomes in latest effort to grow global DCT business
Thread has bought clinical outcomes consultancy Modus Outcomes in a bid to further expand its decentralized trials business.
Site staff diversity vital for trial participant diversity according to Tufts
Clinical trial participant diversity is closely linked with the ethnic diversity of site staff according to research by Tufts Center for the Study of Drug Development (CSDD) in the US.
Europe approves Goldman and EQT’s Parexel takeover
The European Commission has approved Goldman Sachs and EQT’s acquisition of Parexel from Pamplona capital management.
AstraZeneca sets up Indian clinical data insights division
AstraZeneca has set up an insights division in Bengaluru, India to manage some “data-related aspects” of clinical trials.
Blackstone buys Australian Phase I trial firm Nucleus Network
The Blackstone Group has acquired Nucleus Network, an Australian Phase I clinical trials business from Crescent Capital Partners.
Advarra launches site selection platform
Advarra has launched a platform to help trial sponsors identify sites that fit their clinical programs.
IQVIA expects growing decentralized trial business to boost margins
IQVIA says profit margins will improve thanks to decentralized clinical trials, which it says are becoming an increasingly important part of its research services business.
Parexel partners in Japan for decentralized trials and regenerative medicines
Parexel has teamed with Kyoto University Hospital in Japan to promote novel trial approaches and tap demand for cell and gene therapy studies.
Pacific Cancer Care to use AI to find trial patients in Deep Lens deal
The Pacific Cancer Care has teamed with patient recruitment specialist Deep Lens to use artificial intelligence technologies to expand its clinical trial programs.
Shift to remote trials accelerating but new hurdles emerging
Most sponsors and CROs are using decentralized trial technology but more data management work needs to be done to take full advantage of the approach according to new research.
Decentalized trials ideal for Australia say ObvioHealth and Anatara
Anatara Lifesciences has hired “virtual” research organization ObvioHealth Partners for what the firms claim is a first of its kind hybrid clinical trial.
Syneos buys RxDataScience citing trials and product lifecycle business
Syneos Health has bought artificial intelligence and analytics firm RxDataScience with decentralized trials and product lifecycles services in mind.
FDA raises concerns about two Indian CROS, calls for study repetition
The US FDA wants several drug firms to repeat studies over concerns about data generated by CROs Synchron Research Services and Panexcell Clinical Lab.
Emmes: Demand for COVID-19 trial service will continue
Emmes predicts demand for COVID-19 related trials and development work will continue as industry seeks to develop treatments for emerging viral variants.
Curavit joins decentralized trials group, predicts demand will keep growing
Curavit has joined the Decentralized Trials & Research Alliance, an industry-backed non-profit organization focused on the promotion of remote studies.
Icon gets €4m from Ireland to build decentralized trial business
The Irish Government has given Icon €4m to boost its decentralized clinical trial and technology business.
Velocity buys VitaLink and NRI to expand US site network
Velocity Clinical Research has bought VitaLink Research and the National Research Institute expanding its network of US trial sites.
Thread launches decentralized trial consulting service
Decentralized trials are here to stay according to tech firm Thread, which has set up a consulting service to help drug developers make best use of the approach.